公开(公告)号：US07142881B2

公开(公告)日：2006-11-28

申请号：US10373496

申请日：2003-02-20

申请人： Toru Sekino ,  Toru Imamura

发明人： Toru Sekino ,  Toru Imamura

IPC分类号： H04M1/00 ,  H04Q7/20 ,  H04L12/66

CPC分类号： H04W28/06 ,  H04W28/18 ,  H04W88/181

摘要： When communications between mobile terminals MS1 and MS2 are terminated, a TRAU1 judges whether the communications between mobile terminals MS1 and MS2 are synchronous and notifies the mobile terminal MS1 of this information through both a base station control center BSC1 and a base station BTS. The mobile terminal MS1 stores this information in relation to both the dial number of the mobile terminal MS2 and a voice-encoding type used in communications with the mobile terminal MS2. Similarly, a TRAU2 transmits the same information to the mobile terminal MS2 and the mobile terminal MS2 stores this information along with the dial number of the mobile terminal MS1 and a voice-encoding type. When the mobile terminals MS1 and MS2 communicate the second time, communications are conducted using another voice-encoding type if the communications are asynchronous and using the previous voice-encoding type if the communications are synchronous, based on the information stored in this way.

摘要翻译： 当移动终端MS 1和MS 2之间的通信终止时，TRAU1判断移动终端MS 1和MS 2之间的通信是否同步，并通过基站控制中心BSC 1和移动终端MSC通知移动终端MS 1该信息。 基站BTS。 移动终端MS1存储关于移动终端MS 2的拨号号码和在与移动终端MS 2通信中使用的语音编码类型的信息。 类似地，TRAU2向移动终端MS 2发送相同的信息，并且移动终端MS 2与移动终端MS 1的拨号号码和语音编码类型一起存储该信息。 当移动终端MS 1和MS 2第二次通信时，如果通信是异步的，则使用另一个语音编码类型进行通信，并且如果通信是同步的，则使用先前的语音编码类型，基于以这种方式存储的信息 。

公开(公告)号：US20070049306A1

公开(公告)日：2007-03-01

申请号：US11591836

申请日：2006-11-02

申请人： Toru Sekino ,  Toru Imamura

发明人： Toru Sekino ,  Toru Imamura

IPC分类号： H04B7/00

CPC分类号： H04W28/06 ,  H04W28/18 ,  H04W88/181

摘要： When communications between mobile terminals MS1 and MS2 are terminated, a TRAU1 judges whether the communications between mobile terminals MS1 and MS2 are synchronous and notifies the mobile terminal MS1 of this information through both a base station control center BSC1 and a base station BTS. The mobile terminal MS1 stores this information in relation to both the dial number of the mobile terminal MS2 and a voice-encoding type used in communications with the mobile terminal MS2. Similarly, a TRAU2 transmits the same information to the mobile terminal MS2 and the mobile terminal MS2 stores this information along with the dial number of the mobile terminal MS1 and a voice-encoding type. When the mobile terminals MS1 and MS2 communicate the second time, communications are conducted using another voice-encoding type if the communications are asynchronous and using the previous voice-encoding type if the communications are synchronous, based on the information stored in this way.

摘要翻译： 当移动终端MS 1和MS 2之间的通信终止时，TRAU1判断移动终端MS 1和MS 2之间的通信是否同步，并通过基站控制中心BSC 1和移动终端MSC通知移动终端MS 1该信息。 基站BTS。 移动终端MS1存储关于移动终端MS 2的拨号号码和在与移动终端MS 2通信中使用的语音编码类型的信息。类似地，TRAU 2向移动终端发送相同的信息 MS2和移动终端MS2将该信息与移动终端MS 1的拨号号码和语音编码类型一起存储。 当移动终端MS 1和MS 2第二次通信时，如果通信是异步的，则使用另一个语音编码类型进行通信，并且如果通信是同步的，则使用先前的语音编码类型，基于以这种方式存储的信息 。

公开(公告)号：US5874254A

公开(公告)日：1999-02-23

申请号：US822573

申请日：1997-03-19

申请人： Toru Imamura ,  Syuichi Oka ,  Kazuo Ozawa ,  Chieri Sato ,  Seigo Suzuki

发明人： Toru Imamura ,  Syuichi Oka ,  Kazuo Ozawa ,  Chieri Sato ,  Seigo Suzuki

IPC分类号： A61K38/00 ,  C07K14/50 ,  C12N15/16 ,  A61K38/18

CPC分类号： C07K14/50 ,  A61K38/00

摘要： The present invention relates to a novel FGF-5 analogous protein derived from mature mRNA formed by directly binding exon 1 to exon 3 in the splicing of a gene coding for FGF-5 protein as well as to a pharmaceutical composition containing the same as an active ingredient. The pharmaceutical composition containing the novel FGF-5 analogous protein of the present invention as an active ingredient can regulate physiological functions of FGF-5, such as regulation of restoration or development of hairs on the head and body, regulation of trophic and functional regulation in the brain and nervous system, proliferation of fibroblasts, etc.

摘要翻译： 本发明涉及从编码FGF-5蛋白的基因剪接中直接结合外显子1至外显子3而形成的成熟mRNA的新型FGF-5类似蛋白，以及含有该FGF-5蛋白的药物组合物 成分。 含有本发明的新型FGF-5类似蛋白质作为活性成分的药物组合物可以调节FGF-5的生理功能，例如调节头部和身体上毛发的恢复或发育，调节营养和功能调节 脑和神经系统，成纤维细胞的增殖等

公开(公告)号：US20100184665A1

公开(公告)日：2010-07-22

申请号：US12594210

申请日：2008-04-07

申请人： Masashi Suzuki ,  Toru Imamura ,  Yuriko Uehara ,  Kaori Motomura ,  Junko Oki ,  Syuichi Oka ,  Masahiro Asada ,  Akiko Kuramochi ,  Miho Kimura

发明人： Masashi Suzuki ,  Toru Imamura ,  Yuriko Uehara ,  Kaori Motomura ,  Junko Oki ,  Syuichi Oka ,  Masahiro Asada ,  Akiko Kuramochi ,  Miho Kimura

IPC分类号： A61K38/16 ,  C07K14/00 ,  C07H21/04 ,  A61K31/7088 ,  A61P3/10 ,  C12Q1/68

CPC分类号： G01N33/6893 ,  A61K31/727 ,  A61K38/1825 ,  A61K38/47 ,  A61K45/06 ,  C12N9/2434 ,  C12N9/2445 ,  C12N2503/02 ,  C12Y302/01021 ,  C12Y302/01031 ,  G01N2333/50 ,  G01N2500/10 ,  G01N2800/044 ,  A61K2300/00

摘要： Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.

摘要翻译： 使用βKlotho或增加或抑制βKlotho活性作为用于控制由FGF受体介导的FGF21的活性的药剂的物质，本发明提供包含这种βKlotho或这种物质作为活性成分的药物组合物，特别是用于 抗代谢综合征，特别是与控制血糖水平相关的治疗或预防用药物组合物。 此外，本发明提供了用于增强或抑制βKlotho活性的物质，FGF21样活性物质和βKlotho样活性物质的筛选系统，其使用已表达FGF受体的细胞系和/ 或其表面上的βKlotho。

公开(公告)号：US20100183733A1

公开(公告)日：2010-07-22

申请号：US12527693

申请日：2008-02-19

申请人： Toru Imamura ,  Miho Kimura ,  Mitsuko Kawano ,  Nazomi Tsujino ,  Akiko Kuramochi ,  Yuko Oda ,  Kaori Motomura ,  Masashi Suzuki ,  Masahiro Asada ,  Azusa Kameyama ,  Sumie Togayachi ,  Syuichi Oka

发明人： Toru Imamura ,  Miho Kimura ,  Mitsuko Kawano ,  Nazomi Tsujino ,  Akiko Kuramochi ,  Yuko Oda ,  Kaori Motomura ,  Masashi Suzuki ,  Masahiro Asada ,  Azusa Kameyama ,  Sumie Togayachi ,  Syuichi Oka

IPC分类号： A61K8/98 ,  C07K14/50 ,  A61K8/64 ,  A61Q9/04 ,  C12N15/63 ,  C12Q1/68

CPC分类号： C07K14/43536 ,  A61K8/64 ,  A61Q7/02 ,  G01N33/566 ,  G01N2333/50 ,  G01N2500/10

摘要： A hair removing agent or a hair growth inhibiting agent is provided by determining an endogenous factor having a hair growth inhibitory activity, screening for substances having an activity similar to that of the endogenous factor or substances enhancing the activity or expression of the endogenous factor, and utilizing the physiological activities of such substances. It has been found that FGF18 inhibits hair growth. A method of screening for FGF18-like active substances, substances that promote the activity of FGF18 or substances that promote the expression of FGF18 to thereby obtain candidates for the hair growth inhibiting agent or hair removing agent is disclosed. Also disclosed is a hair growth inhibiting agent or a hair removing agent comprising, as an active ingredient, FGF18 and/or an FGF18 partial peptide, or an FGF18-like active substance and/or a substance that promotes the activity or expression of FGF18 (e.g., Digenea simplex extract).

摘要翻译： 通过测定具有毛发生长抑制活性的内源性因子，筛选具有与内源因子相似的活性的物质或增强内源性因子的活性或表达的物质来提供脱毛剂或毛发生长抑制剂，以及 利用这些物质的生理活性。 已经发现FGF18抑制毛发生长。 公开了筛选FGF18样活性物质的方法，促进FGF18活性的物质或促进FGF18表达的物质，从​​而获得毛发生长抑制剂或脱毛剂的候选物。 还公开了一种毛发生长抑制剂或脱毛剂，其包含作为活性成分的FGF18和/或FGF18部分肽或FGF18样活性物质和/或促进FGF18活性或表达的物质（ 例如，Digenea单克隆提取物）。

公开(公告)号：US07589060B2

公开(公告)日：2009-09-15

申请号：US11662897

申请日：2005-09-08

申请人： Toru Imamura ,  Mitsuko Kawano ,  Akiko Kuramochi ,  Masashi Suzuki ,  Masahiro Asada

发明人： Toru Imamura ,  Mitsuko Kawano ,  Akiko Kuramochi ,  Masashi Suzuki ,  Masahiro Asada

IPC分类号： C07K14/50 ,  A61K38/18

CPC分类号： A61K38/1825 ,  A61K8/606 ,  A61K8/64 ,  A61K45/06 ,  A61K48/00 ,  A61Q7/00 ,  C07K14/50 ,  G01N33/5023 ,  G01N2333/50

摘要： It is intended to elucidate the effect of promoting hair follicle growth and to provide the following therapeutic agents for hair-related problems (1) to (3): (1) a hair growth promoting agent, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide; (2) a hair regrowth promoting agent, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide; and (3) a therapeutic agent for alopecia, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide.

摘要翻译： 旨在阐明促进毛囊生长的效果并提供以下用于毛发相关问题的治疗剂（1）至（3）：（1）毛发生长促进剂，其包含作为活性成分的表达载体，其包含 全长FGF-18，其部分肽或编码全长FGF-18或部分肽的cDNA; （2）一种毛发再生促进剂，其包含作为活性成分的包含全长FGF-18的表达载体，其部分肽或编码全长FGF-18或部分肽的cDNA; 包括作为活性成分的包含全长FGF-18，部分肽或编码全长FGF-18或部分肽的cDNA的表达载体作为活性成分。

公开(公告)号：US06769020B2

公开(公告)日：2004-07-27

申请号：US09742872

申请日：2000-12-21

申请人： Tomiya Miyazaki ,  Kazuo Yahiro ,  Toru Imamura ,  Masafumi Tanaka ,  Yutaka Takeda ,  Keisuke Ogata ,  Takuji Tsujigawa ,  Akitoshi Aritaka

发明人： Tomiya Miyazaki ,  Kazuo Yahiro ,  Toru Imamura ,  Masafumi Tanaka ,  Yutaka Takeda ,  Keisuke Ogata ,  Takuji Tsujigawa ,  Akitoshi Aritaka

IPC分类号： G06F1300

CPC分类号： H04L65/104 ,  H04L29/06027 ,  H04L65/103 ,  H04L65/1069 ,  H04L65/4084 ,  H04L65/602 ,  H04L67/16 ,  H04M3/493 ,  H04M15/56 ,  H04M15/8083 ,  H04M2215/0184 ,  H04M2215/202 ,  H04M2215/22 ,  Y10S379/90

摘要： A data terminal, a data distributing system, and an Internet telephoning system are provided where desired data such as advertisements can selectively be determined and used for enjoying its relevant services. The data terminal receives a summary of service data from a data provider apparatus over the Internet, and if desired, demands the data provider apparatus to provide the service data over the Internet. The service data from the data provider apparatus may selectively be received in at least one of an audio form, a text form, and a video form at the data terminal. The service data may be advertisement data, commercial product data, and entertainment data such as music, movies, and games. The entertainment data may selectively be presented as at least one of the title, the artist name, the cost, and a trial sample piece of the content.

公开(公告)号：US08697369B2

公开(公告)日：2014-04-15

申请号：US12594210

申请日：2008-04-07

申请人： Masashi Suzuki ,  Toru Imamura ,  Yuriko Uehara ,  Kaori Motomura ,  Junko Oki ,  Syuichi Oka ,  Masahiro Asada ,  Akiko Kuramochi ,  Miho Kimura

发明人： Masashi Suzuki ,  Toru Imamura ,  Yuriko Uehara ,  Kaori Motomura ,  Junko Oki ,  Syuichi Oka ,  Masahiro Asada ,  Akiko Kuramochi ,  Miho Kimura

IPC分类号： C12Q1/68

CPC分类号： G01N33/6893 ,  A61K31/727 ,  A61K38/1825 ,  A61K38/47 ,  A61K45/06 ,  C12N9/2434 ,  C12N9/2445 ,  C12N2503/02 ,  C12Y302/01021 ,  C12Y302/01031 ,  G01N2333/50 ,  G01N2500/10 ,  G01N2800/044 ,  A61K2300/00

摘要： Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.

摘要翻译： 使用βKlotho或增加或抑制βKlotho活性作为用于控制由FGF受体介导的FGF21的活性的药剂的物质，本发明提供包含这种βKlotho或这种物质作为活性成分的药物组合物，特别是用于 抗代谢综合征，特别是与控制血糖水平相关的治疗或预防用药物组合物。 此外，本发明提供了用于增强或抑制βKlotho活性的物质，FGF21样活性物质和βKlotho样活性物质的筛选系统，其使用已表达FGF受体的细胞系和/ 或其表面上的βKlotho。

公开(公告)号：US06704309B1

公开(公告)日：2004-03-09

申请号：US09216736

申请日：1998-12-21

申请人： Noriaki Nada ,  Takao Miyazaki ,  Kazuo Yahiro ,  Toshinori Yamagichi ,  Takuji Tujigawa ,  Yasuyuki Nishioka ,  Yuji Jodoi ,  Hidetoshi Hayashida ,  Daisuke Wada ,  Toru Imamura

发明人： Noriaki Nada ,  Takao Miyazaki ,  Kazuo Yahiro ,  Toshinori Yamagichi ,  Takuji Tujigawa ,  Yasuyuki Nishioka ,  Yuji Jodoi ,  Hidetoshi Hayashida ,  Daisuke Wada ,  Toru Imamura

IPC分类号： H04L1256

CPC分类号： H04L12/2876 ,  H04L12/2856 ,  H04L12/2898 ,  H04M7/0033 ,  H04M7/128 ,  H04M7/129

摘要： An Internet telephone apparatus which is capable of processing an Internet connection to an Internet telephone or to personal computer communications without requiring the installation of an additional public line, so that a cost for extension of a line and maintenance of the extended line can be eliminated. This Internet telephone apparatus has an incoming call determination unit for determining, based on information in a call setting message from a user, generated when a call is originated, whether the call is an incoming call directed to an access server for controlling communications such as personal computer communications or the like or an incoming call directed to an Internet telephone control unit for controlling the Internet telephone.

摘要翻译： 一种互联网电话设备，其能够处理互联网连接到因特网电话或个人计算机通信，而不需要安装额外的公共线路，从而可以消除延长线路的费用和延长线路的维护。 该互联网电话设备具有来电确定单元，用于基于来自用户的呼叫设置消息中的信息来确定在呼叫发起时产生的呼叫，呼叫是否是来往用于控制诸如个人之类的通信的接入服务器的呼入 计算机通信等，或者是指向互联网电话控制单元的来电，用于控制因特网电话。

公开(公告)号：US06624146B1

公开(公告)日：2003-09-23

申请号：US09720039

申请日：2001-04-04

申请人： Toru Imamura ,  Ai-Jun Li ,  Akiko Kuramochi ,  Hiroyuki Tsuboyama

发明人： Toru Imamura ,  Ai-Jun Li ,  Akiko Kuramochi ,  Hiroyuki Tsuboyama

IPC分类号： A61K3800

CPC分类号： A61K38/1825

摘要： The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a peptide represented by the following formula (I): MTS-X-NLS  (I) wherein MTS represents a membrane-transfer amino acid sequence; X represents a direct bond or a linker sequence; and NLS represents a nuclear localization amino acid sequence, or a pharmaceutically acceptable salt thereof, particularly, a pharmaceutical composition having food and water intake inhibitory effects, and accompanying weight-reducing and obesity-inhibiting effects.

摘要翻译： 本发明涉及一种药物组合物，其包含作为活性成分的由下式（I）表示的肽：其中MTS表示膜转移氨基酸序列; X表示直接键或连接序列; 并且NLS表示核定位氨基酸序列或其药学上可接受的盐，特别是具有食物和水摄取抑制作用的药物组合物，以及伴随的减肥和肥胖抑制作用。